The success of KIT-targeting imatinib mesylate in the treatment of GIST [16] and chronic myelogenous leukemia [17] may be relevant for DG treatment [18]. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.